ATyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
ATyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor's section of the company's website at . Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact investorrelations@atyrpharma.com.SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA.
聖地亞哥，2024年12月17日（環球新聞網）-- aTyr Pharma, Inc.（納斯達克：ATYR），一家處於臨床階段的生物技術公司，致力於從其專有的tRNA合成酶平台進行首創藥物的發現和開發，今天宣佈，總裁兼首席執行官Sanjay S. Shukla萬.D.萬.S.將在定於2025年1月13日至16日在加利福尼亞州舊金山舉行的第43屆J.P.摩根醫療保健大會上進行演講。
Details of the presentation appear below:
演講的詳細信息如下：
Conference: 43rd Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 16, 2025
Time: 8:15am PST
Location: San Francisco, CA
Format: Corporate Presentation
會議：第43屆J.P.摩根醫療保健大會
日期：2025年1月16日，星期四
時間：太平洋標準時間上午8:15
地點：加州舊金山
格式：公司演示
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor's section of the company's website at . Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact investorrelations@atyrpharma.com.
除了演示，公司管理層將會參與與註冊會議的投資者進行一對一的會議。演示的網絡直播將在公司網站的投資者部分提供。活動後，演示的重播將在aTyr網站上提供至少30天。如需更多信息，請聯繫 investorrelations@atyrpharma.com。
About aTyr
關於aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr's lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit .
aTyr是一家處於臨床階段的生物技術公司，利用進化智能將tRNA合成酶生物學轉化爲治療纖維化和炎症的新療法。tRNA合成酶是古老且必不可少的蛋白質，已經進化出獨特的結構域，調節人類多種細胞外通路。aTyr的發現平台專注於通過揭示由其專有的20種tRNA合成酶衍生的結構域驅動的信號通路來解鎖隱藏的治療干預點。aTyr的主要治療候選藥物是efzofitimod，一種首創生物免疫調節劑，正在開發用於治療間質性肺病，這是一組可以導致炎症和肺部漸進性纖維化或瘢痕的免疫介導疾病。如需更多信息，請訪問。
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
聯繫：
Ashlee Dunston
董事，投資者關係和公共事務
adunston@atyrpharma.com
譯文內容由第三人軟體翻譯。
